Reporter brief
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Open-label design without control group cannot establish efficacy or isolate drug effects from placebo response. No outcome data were reported, so no claims about the intervention's effects can be evaluated. The study design and population do not determine whether senolytics specifically address aging in psychiatric conditions or only depression/schizophrenia symptoms.
Study design and sample
Other; Human.
Not recorded.
- Design
- Other
- Sample
- —
- Journal
- Washington University School of Medicine
- Published
- Apr 21, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.